A Single-center, Randomized, Open, Single-dose, Two-cycle, Two-sequence Crossover Food Effect Study of SPH5030 Tablets in Healthy Chinese Adult Subjects
Latest Information Update: 22 Apr 2024
At a glance
- Drugs SPH 5030 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Shanghai Pharmaceuticals Holding
- 22 Apr 2024 New trial record